Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

Terminated

• Conditions: Epilepsy; Vitamin D Deficiency; Magnesium Deficiency

• Registration Number: NCT03471481
• Lead Sponsor: Drexel University

Brief Summary

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-08-10
• Study First Submitted: 2018-03-14
• Study First Submitted QC: 2018-03-14
• Study First Posted: 2018-03-20
• Primary Completion: 2019-08-01
• Study Completion: 2019-08-01
• Status Verified: 2019-11
• Last Update Submitted: 2021-02-25
• Last Update Posted: 2021-03-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

• Individuals receiving anti-epileptic drugs as a treatment for epilepsy

Read More

Exclusion Criteria

• Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bone mineral density	1 time point - baseline	Will be measured at Tibia, Hip and Total Body using a DXA scan

Secondary Outcome Measures

Name	Time	Method
Vitamin D - 25 hydroxy vitamin D	1 time point - baseline	This will be assayed in the serum
Ionized Magnesium in serum	1 time point - baseline	This will be assayed in the serum

Trial Locations

Locations (2)

Drexel University Nutrition Sciences Research Lab; 🇺🇸 Philadelphia, Pennsylvania, United States

Drexel University; 🇺🇸 Philadelphia, Pennsylvania, United States